Copyright in Biology: Intellectual Property and Ethical Issues | 生物学中的版权：知识产权与伦理问题

📚 Copyright in Biology: Intellectual Property and Ethical Issues | 生物学中的版权：知识产权与伦理问题

In modern biology, the line between discovery and ownership has become increasingly blurred. From gene sequences to CRISPR technology, intellectual property (IP) rights such as patents and copyrights now cover living material and medical breakthroughs. Understanding this intersection is vital for A-Level Biology students, as it raises profound ethical, legal, and economic questions.

在现代生物学中，发现与所有权的界限日益模糊。从基因序列到CRISPR技术，专利和版权等知识产权如今已涵盖生命材料与医学突破。理解这一交叉领域对A-Level生物学学生至关重要，因为它引发了深刻的伦理、法律和经济问题。

1. What Is Intellectual Property in Biology? | 什么是生物学中的知识产权？

Intellectual property in biology refers to legal rights granted to inventors and researchers over their biological discoveries. These rights may include patents on genes, copyright on software used for DNA analysis, and trade secrets protecting biotechnological processes. The aim is to encourage innovation by allowing temporary commercial exclusivity.

生物学中的知识产权是指授予发明者和研究者对其生物学发现的法律权利。这些权利可包括基因专利、DNA分析软件的版权，以及保护生物技术过程的商业秘密。其目的是通过给予临时商业排他权来鼓励创新。

In the UK and Europe, biological patents are governed by strict criteria: the invention must be novel, involve an inventive step, and be capable of industrial application. However, ethical boundaries restrict patenting of human embryos, methods of human cloning, and processes that could cause animal suffering without significant medical benefit.

在英国和欧洲，生物专利受严格标准约束：发明必须具有新颖性、创造性步骤，并能够在工业上应用。然而，伦理界限限制了对人类胚胎、人类克隆方法以及可能造成动物痛苦而无重大医学益处的方法授予专利。

2. Gene Patents: The Controversy Over Owning Life | 基因专利：拥有生命的争议

Gene patents grant a company or individual exclusive rights to isolated and purified gene sequences. The most famous example was the BRCA1 and BRCA2 gene patents held by Myriad Genetics, which gave the company control over testing for breast cancer susceptibility. This meant patients could only access the test through Myriad, often at very high prices.

基因专利授予公司或个人对分离并纯化的基因序列的独占权。最著名的例子是Myriad Genetics持有的BRCA1和BRCA2基因专利，这使得该公司控制了乳腺癌易感性检测。这意味着患者只能通过Myriad进行检测，且价格通常非常高昂。

In 2013, the US Supreme Court ruled that naturally occurring DNA sequences cannot be patented, though synthetic complementary DNA (cDNA) can. The European Patent Office also restricts gene patents to sequences with a demonstrated specific function, not raw genomic data. This debate touches on a core biological concept: is a gene a product of nature or a human invention?

2013年，美国最高法院裁定自然存在的DNA序列不可申请专利，但合成的互补DNA（cDNA）可以。欧洲专利局也将基因专利限制在已证明有特定功能的序列，而非原始基因组数据。这场争论触及一个核心生物学概念：基因是自然的产物还是人类的发明？

3. The CRISPR Patent Battle | CRISPR基因编辑技术的专利之争

CRISPR-Cas9 technology, a revolutionary gene-editing tool derived from bacterial immune systems, sparked one of the fiercest IP disputes in biology. The Broad Institute (MIT and Harvard) and the University of California (UC) filed competing patents, each claiming first discovery of CRISPR’s use in eukaryotic cells.

CRISPR-Cas9技术是一项源自细菌免疫系统的革命性基因编辑工具，引发了生物学界最激烈的知识产权争端之一。博德研究所（麻省理工和哈佛）和加州大学分别提交了竞争性专利，各自声称最先发现CRISPR在真核细胞中的用途。

In the US, the Broad Institute was awarded key patents because of its narrower but earlier demonstration in eukaryotic cells. In Europe, UC’s broader patent was initially upheld. This legal chess game illustrates how IP frameworks struggle to keep pace with fast-evolving biological techniques, and how patent ownership can steer the direction of global research funding.

在美国，博德研究所因较早且精确地证明在真核细胞中的应用而获得了关键专利。在欧洲，加州大学更广泛的专利最初得到支持。这场法律博弈说明知识产权框架难以跟上快速发展的生物技术，以及专利所有权如何引导全球研究资金的走向。

4. Drug Patents and Access to Medicines | 药物专利与药物可及性

Pharmaceutical companies invest billions in drug development, relying on patents to recoup costs through temporary monopolies. A typical drug patent lasts 20 years from filing, giving exclusive sales rights. This drives innovation but can make life-saving treatments unaffordable in low-income countries.

制药公司在药物研发上投入数十亿美元，依靠专利通过暂时垄断收回成本。典型药物专利从申请日起有效期为20年，提供独家销售权。这推动了创新，但可能使挽救生命的治疗在低收入国家难以负担。

The Doha Declaration on TRIPS and Public Health (2001) affirmed that WTO members can override drug patents during public health emergencies through compulsory licensing. This allowed countries to produce generic antiretroviral drugs for HIV/AIDS, dramatically lowering costs. For A-Level Biology, this ties into pharmacology and infectious disease topics, highlighting the role of ethics in medicine.

《关于TRIPS协议与公共健康的多哈宣言》（2001年）确认，世贸组织成员可在公共卫生紧急情况下通过强制许可超越药品专利。这使得各国能生产治疗HIV/AIDS的仿制药，大幅降低了成本。对A-Level生物学而言，这与药理学和传染病主题相关联，突显了医学中的伦理角色。

5. Seed Copyrights and Agricultural Biotechnology | 农业生物技术中的种子版权

Genetically modified (GM) seeds are often protected by patents and Plant Breeders’ Rights. Companies like Monsanto (now Bayer) patent GM traits such as herbicide resistance or insecticidal Bt toxin production. Farmers who purchase these seeds typically sign agreements not to save and replant seeds, ensuring annual repurchases.

转基因（GM）种子通常受专利和植物育种者权利保护。像孟山都（现属拜耳）这样的公司，对耐除草剂或产生杀虫Bt毒素等转基因性状申请了专利。购买这些种子的农民通常需签署协议，不得留种再种，以确保年度购买。

This has led to debates about biodiversity, food sovereignty, and the impact on smallholder farmers in developing nations. Biologically, the technology relies on recombinant DNA techniques and selective markers like antibiotic resistance genes. Critics argue that too-powerful seed patents stifle agricultural research and concentrate power in a few corporations.

这引发了对生物多样性、粮食主权以及对发展中国家小农影响的争论。从生物学角度看，该技术依赖重组DNA技术和抗生素抗性基因等选择标记。批评者认为，过于强大的种子专利扼杀了农业研究，并将权力集中在少数公司手中。

6. Biopiracy: Exploitation of Traditional Knowledge | 生物剽窃：对传统知识的剥削

Biopiracy occurs when companies patent biological resources or traditional knowledge from indigenous communities without fair compensation. For example, the neem tree (Azadirachta indica), used for centuries in India for its medicinal and pesticidal properties, became the subject of numerous patents by Western companies.

生物剽窃是指公司未经公平补偿，就对来自原住民社区的生物资源或传统知识申请专利。例如，楝树（Azadirachta indica）在印度被用于医药和杀虫已有数百年历史，却成了西方公司多项专利的主题。

This raises questions about ownership of naturally occurring substances and the rights of original stewards. The Convention on Biological Diversity (CBD) now requires benefit-sharing and prior informed consent for accessing genetic resources. A-Level biologists should see this as an example of how ecology and anthropology intersect with ethics and IP law.

这引发了对天然物质所有权和原始守护者权利的问题。《生物多样性公约》现在要求获取遗传资源需进行惠益分享并事先知情同意。A Level生物学学生应将此视为生态学、人类学与伦理和知识产权法相交织的一个例子。

7. Open Science and Data Sharing | 开放科学与数据共享

In response to restrictive IP, there is a growing movement toward open science in biology. The Human Genome Project famously made its sequence data publicly available within 24 hours of generation, refusing to patent the results. This ethos continues with open-access journals, freely available genetic databases, and the sharing of CRISPR constructs through non-profit repositories like Addgene.

为应对限制性的知识产权，生物学界正兴起一场开放科学运动。人类基因组计划的做法广为人知，它在产生序列数据后24小时内将其公之于众，拒绝为结果申请专利。这一精神延续至开放获取期刊、免费可用的基因数据库以及通过Addgene等非营利存储库共享CRISPR构建体。

Open science accelerates discovery, democratises access, and fosters collaboration. However, it can conflict with commercial incentives. The COVID-19 pandemic saw unprecedented global sharing of viral genome sequences, demonstrating how openness can enable rapid vaccine development. This is a powerful lesson about the value of unpatented biological information.

开放科学能促进发现、实现资源共享民主化并促进合作。然而，它可能与商业激励相冲突。COVID-19大流行期间，病毒基因组序列以前所未有的全球规模共享，证明了开放如何促成疫苗快速研发。这是关于未申请专利的生物学信息价值的有力一课。

8. Ethical Frameworks and Future Outlook | 伦理框架与未来展望

Several ethical principles guide IP decisions in biology: justice (fair access), beneficence (maximising benefit), non-maleficence (avoiding harm), and respect for autonomy. When assessing whether to patent a biological discovery, one must weigh commercial reward against possible harms to public health, research freedom, and cultural rights.

有几项伦理原则指导生物学领域的知识产权决策：公正（公平获取）、行善（使利益最大化）、不作恶（避免伤害）以及尊重自主权。在评估是否对一项生物学发现授予专利时，必须权衡商业回报与可能对公共健康、研究自由和文化权利造成的伤害。

New technologies like synthetic biology and gene drives will push these boundaries further. What if an engineered organism designed to eliminate malaria vectors accidentally crosses borders? Who owns the solution? A-Level syllabuses increasingly include bioethics, so understanding the IP landscape is essential for any future biologist or informed citizen.

合成生物学和基因驱动等新技术将进一步突破这些界限。如果一种旨在消灭疟疾病媒的工程生物不小心跨越国界怎么办？谁拥有解决方案？A-Level大纲越来越多地纳入生物伦理，因此了解知识产权格局对未来生物学家或具知情权的公民而言至关重要。

9. How Does This Link to Your A-Level Biology Course? | 这与你的A-Level生物学课程有什么联系？

While intellectual property is not a standalone topic, it appears across the Cambridge International A-Level Biology syllabus in contexts such as genetic technology, drug development, biodiversity and conservation, and ethical decision-making. For example, Paper 5 (Planning, Analysis and Evaluation) might require you to design an investigation involving GM crops, where you must consider legislative constraints.

虽然知识产权并非一个独立的专题，但它出现在剑桥国际A-Level生物学大纲中的多个背景下，如基因技术、药物研发、生物多样性与保护，以及伦理决策。例如，Paper 5（规划、分析和评估）可能要求你设计一项涉及转基因作物的调查，此时需考虑立法限制。

You may be asked to discuss the advantages and disadvantages of patenting genetic information, or to evaluate the impact of drug patents on global health. Reviewing the ethical and legal dimensions adds depth to your extended answers and prepares you for university-level biology where such interdisciplinary topics are common.

你可能会被要求讨论为遗传信息申请专利的利弊，或评估药物专利对全球健康的影响。回顾伦理与法律维度能为你的扩展答案增加深度，并为大学阶段的生物学做好铺垫，因为这类跨学科主题在大学里很常见。

10. Summary and Key Takeaways | 总结与要点回顾

Intellectual property in biology is a double-edged sword: it incentivises innovation but can restrict access to vital treatments and knowledge. Gene patents, CRISPR disputes, drug exclusivity, and agricultural IP all stir ethical debates that A-Level students should be able to critically evaluate. The future will likely see a careful balance between open science and commercial protection, guided by societal values and global agreements.

生物学中的知识产权是一把双刃剑：它激励创新，但也可能限制对关键治疗与知识的获取。基因专利、CRISPR争端、药物排他权以及农业知识产权都会引发A-Level学生应能加以批判评价的伦理辩论。未来可能会出现由社会价值和全球协议引导的开放科学与商业保护之间的一种谨慎平衡。

IP Type	Biological Example	Ethical Concern
Gene Patent	BRCA1/2 (Myriad)	Limits patient choice and increases cost
Drug Patent	Sofosbuvir (Hepatitis C cure)	Unavailable to millions due to price
Plant Breeder’s Right	Roundup Ready soybeans	Creates dependency and reduces seed saving
Copyright	Bioinformatics software	Restricts use of essential research tools

Remember: for Cambridge A-Level Biology, the ability to discuss the social and ethical implications of biological developments is just as important as knowing the facts. Use the examples above to illustrate your arguments.

请记住：对于剑桥A-Level生物学，能够讨论生物发展的社会和伦理意义与了解事实同等重要。请使用上述例子来阐明你的论点。

Published by TutorHao | Biology Revision Series | aleveler.com

更多咨询请联系16621398022（同微信）